卿氏湿疹疱洗方2号治疗血虚风燥型手足慢性湿疹临床疗效观察

目的:探讨卿氏湿疹泡洗方2号对血虚风燥型手足慢性湿疹的效果。方法:选取我院2018年1月-2018年9月血虚风燥型手足慢性湿疹患者116例,根据治疗方案不同分为研究组(58例)和参照组(58例),参照组给予卤米松乳膏联合尿素乳膏,研究组给予卿氏湿疹疱洗方2号联合尿素乳膏,比较两组治疗效果、治疗前后湿疹面积及严重度指数(Eczema Area and Severity Index,EASI)、皮肤病生活质量指数(Dermatology life uality Index,DLQI)及不良反应。结果:研究组治疗总有效率为94.83%(55/58),高于参照组82.76%(48/58)(P<0.05);两组治疗后EASI、DLQI评分均低于治疗前,且研究组低于参照组(P<0.05);两组均未见严重不良反应。结论:卿氏湿疹泡洗方2号治疗血虚风燥型手足慢性湿疹患者疗效确切,可明显改善临床症状,缩小湿疹面积,提高患者生活质量,且不增加不良反应,安全性高,值得临床推广应用。     

宣威地区与非宣威地区肺癌患者临床流行病学特征及病理类型特点分析

目的:分析宣威地区与非宣威地区的肺癌临床流行病学与病理特征。方法:以云南省肿瘤医院（昆明医科大学第三附属医院）2015年3月至2015年5月手术治疗的肺癌患者为研究对象，共295例，收集患者相关信息。将其分为宣威地区、非宣威地区进行统计。对患者的临床资料进行回顾性分析，包含病理类型、年龄、性别、吸烟史等。结果:宣威地区、非宣威地区肺癌患者男女比例为1.19∶1和1.69∶1。宣威地区患者平均年龄为［53.41±8.74(34~85)］岁，中位年龄53岁。非宣威地区肺癌患者平均年龄为［58.68±8.63(38~78)］岁，中位年龄59岁。宣威地区肺癌高发年龄为40~59岁段。宣威地区I期肺癌患者占比、T1期肺癌患者占比、N0期肺癌患者占比均高于非宣威地区。宣威地区男性腺癌鳞癌比远高于非宣威地区，差异有显著统计学意义。结论:宣威地区女性肺癌发病率更高，发病年龄更趋年轻化，腺癌比例高，吸烟与宣威地区男性腺癌高发关系不密切。     

3 404例2型糖尿病患者视网膜病变患病率及其相关因素分析

目的 分析2型糖尿病（T2DM）患者视网膜病变（DR）患病率及其相关因素。方法 对3 404例2型糖尿病住院患者进行回顾性研究，根据眼科会诊结果，将患者分为3组，其中非DR组（A组/NDR组）2 562例，DR非增殖期组（B组/NPDR组）716例，DR增殖期组（C组/PDR组）126例。得出DR的患病率，比较3组患者之间临床资料及临床指标的异同，及其与DR的相关性。结果 2型糖尿病患者DR患病率达24.7%，与甘油三酯（OR=1.110，P=0.000）、糖化血红蛋白（HbA1c）（OR=1.087，P=0.000）、血尿酸（OR=1.003，P=0.000）、病程（OR=1.002，P=0.000）相关。结论 2型糖尿病患者DR患病率为24.7%，高血脂、高血糖、高尿酸血症、病程长为DR的独立危险因素。早期发现糖尿病、早期治疗糖尿病、积极控制血糖血脂血尿酸，对于减少DR的发生及延缓DR的发展意义重大。     

风池穴不同刺法对椎动脉型颈椎病的临床疗效评价

目的:探究风池穴不同刺法对椎动脉型颈椎病的临床疗效。方法:选择2018年4月—2019年1月北京中医药大学东直门医院针灸科门诊就诊的84例椎动脉型颈椎病患者作为研究对象,分为观察组43例、对照组41例。观察组采用短刺法针刺风池穴治疗,对照组采用平补平泻法针刺风池穴治疗,1个疗程后比较两组患者的ESCV、颈椎病症状分级量化表评分以及TCD相关指标,TCD指标观察基底动脉和双侧椎动脉的平均血流速度(Vm)、收缩期血流速度峰值(Vs)、血管搏动指数(PI)和血管阻力指数(RI)的变化。结果:治疗前后两组ESCV、颈椎病症状分级量化表评分比较,差异有统计学意义(P<0.05),且椎动脉、基底动脉的Vs、Vm较治疗前明显减慢,且观察组治疗效果优于对照组(P<0.05)。结论:针刺风池穴治疗椎动脉型颈椎病临床效果显著,且短刺法优于平补平泻法。     

大柴胡汤加味联合西药治疗肥胖型2型糖尿病的临床疗效及对患者胰岛素抵抗的影响

目的:观察大柴胡汤加味联合西药治疗肥胖型2型糖尿病(type 2 diabetes mellitus,T2DM)的临床疗效及对患者胰岛素抵抗的影响。方法:选取2018年3月至2019年3月本院治疗的肥胖型T2DM患者104例,依据随机对照原则分为对照组和试验组,每组52例。对照组给予常规西药治疗,试验组在对照组治疗的基础上加用大柴胡汤加味治疗。结果:试验组总改善率为88.46%,对照组总改善率为73.08%,试验组高于对照组,差异有统计学意义(P<0.05);试验组治疗后胃脘胀满、胸肋胀闷、心烦易怒、口干口苦、体型肥胖、大便秘结等中医证候积分均显著低于对照组,差异有统计学意义(P<0.05);试验组患者治疗后空腹血糖、餐后2 h血糖、糖化血红蛋白、体质量指数均显著低于对照组,差异有统计学意义(P<0.05);试验组治疗后胰岛素抵抗指数低于对照组,胰岛素敏感指数、β-细胞功能指数均高于对照组,差异有统计学意义(P<0.05)。结论:大柴胡汤加味联合西药治疗肥胖型T2DM,可明显改善患者血糖控制效果和胰岛功能。     

Efficacy and Safety of the Modified EPOCH Regimen (Etoposide,Vincristine, Doxorubicin,Carboplatin, and Prednisolone) for Adult T-cell Leukemia/Lymphoma: A Multicenter Retrospective Study

BackgroundWe retrospectively analyzed patients with untreated aggressive adult T-cell leukemia/lymphoma who received the modified EPOCH (mEPOCH) regimen.Patients and MethodsPatients received up to 6 mEPOCH cycles. Etoposide (50 mg/m²/day), doxorubicin (10 mg/m²/day), and vincristine (0.4 mg/m²/day) were each given as a continuous 96-hour infusion on days 1 to 4. Prednisolone (40 mg/m²/day) was given intravenously or orally on days 1 to 4 and then tapered and stopped on day 7, and carboplatin (dose calculated for each patient individually using Calvert’s formula according to a target under the curve of 3 mg/mL/min) was given as a 2-hour intravenous infusion on day 6.ResultsIn 103 patients, overall response rate and complete response rate were 58% and 25%, respectively. With a median follow-up of 8.9 months, the median survival time was 9.8 months (95% confidence interval, 7.2-13.9 months). The median progression-free survival (PFS) was 4.2 months (95% confidence interval, 3.4-5.7 months). Patients who completed ≥ 4 cycles experienced significantly better overall survival and PFS compared with those who completed < 4 cycles. Twenty-eight patients underwent allogeneic hematopoietic stem cell transplantation after mEPOCH and demonstrated significantly prolonged overall survival and PFS compared with those who did not undergo transplantation.ConclusionThe mEPOCH regimen is effective with tolerable adverse effects and may be an alternative treatment option for adult T-cell leukemia/lymphoma.     

补肾壮骨汤对骨质疏松型胸腰椎压缩骨折患者椎体成形术治疗效果影响的Meta分析

[目的]采用Meta分析法系统评价补肾壮骨汤对椎体成形术治疗骨质疏松型胸腰椎压缩骨折(OTCF)临床的影响。[方法]以"补肾壮骨汤"为首输关键词,以"椎体成形术""骨质疏松""胸腰椎压缩骨折"等为次输关键词,全面搜索补肾壮骨汤对OTCF患者椎体成形术治疗效果影响的随机对照研究文献,评价纳入研究文献的一般特征,对文献资料所提取的治疗有效率、骨密度、Oswestry功能障碍(ODI)指数、治疗安全性(新发骨折率)等观察指标进行Meta分析处理与分析。[结果]共13篇文献纳入Meta分析范畴,文献总样本量1 037例。分析显示,与对照组相比,治疗组可明显提高临床有效率[OR=4.63,95%CI[2.92,7.36],P0.000 01]、改善骨密度[MD=0.08,95%CI[0.06,0.1],P0.000 01]、降低ODI指数[MD=-2.34,95%CI[-3.49,-1.19],P0.000 01]、降低新发骨折率[OR=0.08,95%CI[0.11,0.44],P0.000 01]。[结论]与单纯椎体成形术治疗相比,补肾壮骨汤辅助椎体成形术在OTCF患者治疗中,可提升患者术后骨密度、改善胸腰椎功能障碍和降低术后新发骨折率,治疗疗效确切。     

The effect of nettle (Urtica dioica) supplementation on the glycemic control of patients with type 2 diabetes mellitus: A systematic review and meta‐analysis

Type 2 diabetes mellitus (T2DM) is a major health problem, worldwide, that is associated with increased morbidity and mortality. Several randomized controlled clinical trials (RCTs) have investigated the effect of nettle (Urtica dioica) supplementation on markers of glycemic status in patients with T2DM, with conflicting results. Therefore, the present study assessed the effect of nettle on some glycemic parameters in patients with T2DM. A comprehensive search was conducted in PubMed, Scopus, Cochrane Library, and Web of Science, from database inception up to June 2019, to identify RCTs investigating the effect of nettle supplementation on glycemic markers, including fasting blood sugar (FBS) concentrations, insulin levels, homeostasis model assessment‐estimated insulin resistance index, and glycosylated hemoglobin percentage in adults with T2DM. The Cochrane Collaboration tool was used to assess the methodological quality of the included studies. Results of this meta‐analysis were reported based on the random effects model. Eight RCTs, comprising 401 participants, were included in the present systematic review and meta‐analysis. Based on the Cochrane Collaboration risk of bias tool, five studies were considered as good quality, one was fair, and two studies were poor, respectively. The results of the meta‐analysis revealed a significant reduction in FBS concentrations (weighted mean difference [WMD]: ?18.01 mg/dl, 95% confidence interval [CI]: ?30.04 to ?5.97, p < .001, I² = 94.6%) following nettle supplementation. However, no significant reduction was observed in insulin levels (WMD: 0.83 Hedges' g, 95% CI: ?0.26 to 1.92, p = .13, I² = 89.4%), homeostasis model assessment‐estimated insulin resistance index (WMD: ?0.22, 95% CI: ?0.83 to 0.40, p = .49, I² = 69.2%), or glycosylated hemoglobin percentage (WMD: ?0.77%, 95% CI: ?1.77 to 0.22, p = .12, I² = 83.0%). The findings of the present study suggest that nettle supplementation may be effective in controlling FBS for T2DM patients. However, further studies are needed to confirm the veracity of these results.